TABLE 1

Pubertal Growth in 41 Postpubertal Patients With MUL

VariableNatural GrowthGH Therapy
MedianRangeMedianRange
Pubertal stage P2G2/M2, y12.59.2 to 1511.68.8 to 15
Menarche, ya1510.5 to 171210 to 15.5
Height at P2G2/M2, SDS−3.6−6.3 to 1.4−2.9−4.2 to 0.9
WFH at P2G2/M2, %−14−22 to 20−14.5−24 to 11
Height 2 y after P2G2/M2, SDS−3.5−5.8 to 1.3−2.9−5.3 to 1.8
WFH 2 y after P2G2/M2, %−3−21 to 58−8−21 to 20
Adult height, SDS−4.6−6.7 to 2.2−4.0−4.9 to 2.1
WFH at adult height, %20−2 to 753−20 to 34
  • Sixteen patients (8 female) were treated with GH, and 25 had no growth-promoting treatment. GH indicates recombinant human GH at a dose of 0.035 mg/kg per day.

  • a Values are from 21 female subjects: 13 untreated and 8 treated with GH.